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SUMMARY 
Preterm birth, the leading cause of neonatal morbidity and mortality worldwide, is 
frequently preceded by spontaneous preterm labor, a syndrome of multiple 
etiologies. Pathological inflammation is causally linked to spontaneous preterm 
labor. Indeed, direct activation of invariant natural killer T (iNKT) cells via α-
galactosylceramide induces preterm labor/birth largely by initiating systemic and 
local (i.e., decidua and myometrium) innate immune responses. Herein, we 
investigated whether iNKT-cell activation altered local and systemic T-cell subsets. 
Administration of α-galactosylceramide induced an expansion of activated CD1d-
restricted iNKT cells in the decidua, and a reduction in the number of: 1) total T 
cells and conventional CD4+ and CD8+ T cells through the down-regulation of the 
CD3ε molecule in the peripheral circulation, spleen, uterine-draining lymph nodes 
(ULNs), decidua and/or myometrium; 2) CD4+ regulatory T cells in the spleen, 
ULNs, and decidua; 3) Th17 cells in the ULNs but an increase in the number of 
decidual Th17 cells; 4) CD8+ regulatory T cells in the spleen and ULNs, and 5) 
CD4+ and CD8+ Foxp3- responder T cells in the spleen and ULNs. Since 
treatment with rosiglitazone prevents iNKT-cell activation-induced preterm 
labor/birth, we also explored whether the administration of this PPARγ agonist 
would restore the number of T cells. Treating α-galactosylceramide-injected mice 
with rosiglitazone partly restored the number of T cells in the spleen but not in the 
decidua. In summary, iNKT-cell activation altered the systemic and local T–cell 
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subsets prior to preterm labor/birth; yet, treatment with rosiglitazone partially 
reversed such effects.  
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INTRODUCTION 
Preterm birth — delivery before 37 completed weeks of gestation — is the 
leading cause of neonatal morbidity and mortality worldwide (1, 2). Two-thirds of all 
preterm births are preceded by spontaneous preterm labor (3, 4), a syndrome of 
multiple etiologies (5). Pathological inflammation is implicated in the mechanisms 
responsible for spontaneous preterm labor (6-8) and is mostly attributed to the 
activation of the innate limb of immunity (8-16). Indeed, innate lymphocytes, such 
as invariant natural killer T (iNKT) cells, participate in the inflammatory 
mechanisms that lead to preterm labor and birth (17-19). 
iNKT cells express a CD1d-restricted T cell receptor (TCR) that involves the 
selective use of Vα14 in mice (20) and Vα24 in humans (21), both of which 
recognize lipid antigens (22). Activation of iNKT cells can initiate the NF-κΒ 
signaling pathway, which leads to a massive immune response mediated by Th1 
and Th2 cytokines (23-26). In vivo and direct activation of iNKT cells is achieved by 
the administration of the high-affinity ligand α-galactosylceramide (α-GalCer) (27, 
28). Rec ntly, we demonstrated that the in vivo and direct activation of iNKT cells 
via α-GalCer initiates systemic and local (i.e., decidua and myometrium) immune 
responses leading to preterm labor/birth (19). Such responses are largely mediated 
by cellular components of the innate immune system, such as neutrophils, 
macrophages, and dendritic cells (19). Yet, iNKT cells bridge the innate and 
adaptive limbs of immunity (29); therefore, we propose that such cells have an 
effect on T cells, the main cellular component of the adaptive immune system. T 
cells have been implicated in the mechanisms that lead to term (30-34) and 
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preterm (31, 32, 35-42) labor. Indeed, in vivo activation of T cells through the 
activation of the CD3 complex induces preterm labor/birth (43). In the current 
study, we investigated whether iNKT-cell activation via α-GalCer has an effect on 
systemic and local T-cell subsets prior to preterm labor/birth. 
In vivo iNKT-cell activation via α-GalCer downregulates the expression of 
peroxisome proliferator-activated receptor gamma (PPARγ) target genes such as 
Fabp4 and Fatp4 (19). Yet, treatment with rosiglitazone, a selective PPARγ agonist 
(44), restores the expression of such genes and reduces the rate of iNKT-cell 
activation-induced preterm labor/birth (19). Rosiglitazone activates the PPARγ 
pathway, which interferes with the nuclear factor (NF)-κB, signal transducer and 
activator of transcription (STAT), and activator protein (AP)-1 signaling pathways, 
inhibiting the gene transcription of inflammatory mediators (45-47). Herein, we 
investigated whether treatment with rosiglitazone restores the effect of iNKT-cell 
activation on local and systemic T-cell subsets.  
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MATERIALS AND METHODS 
Animals 
C57BL/6J (B6) mice were bred in the animal care facility at the C.S. Mott 
Center for Human Growth and Development (Wayne State University, Detroit, MI, 
USA) and housed under a circadian cycle (12hrs light:12hrs dark). Females 8-12 
weeks old were mated with males of proven fertility. Females were examined daily 
between 8:00 a.m. and 9:00 a.m., and mating was verified by the presence of a 
vaginal plug, indicating 0.5 days post coitum (dpc). After observation of the vaginal 
plug, females were separated from the male and placed in new cages. A weight 
gain of >2 grams by 12.5 dpc confirmed pregnancy. Procedures were approved by 
the Institutional Animal Care and Use Committee (IACUC) at Wayne State 
University (Protocol Number A-09-08-12). 
 
iNKT-cell activation-induced preterm labor/birth model 
Pregnant B6 mice were intravenously (i.v.) injected with 2 µg of α-GalCer 
(KRN7000; Funakoshi, Tokyo, Japan; n=8) that was dissolved in 50 µL of 4% 
Dimethyl Sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) or with 50 µL of 
4% DMSO alone as a control (n=6) at 16.5 dpc.  
 
Rosiglitazone treatment  
Pregnant B6 mice were i.v. injected with 2 µg of α-GalCer at 16.5 dpc (n=8). 
After 2 h, mice were subcutaneously (s.c.) injected with rosiglitazone (10 mg/kg, 
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Selleck Chemicals, Houston, TX, USA) diluted in 1:10 DMSO. Control mice were 
treated with rosiglitazone alone at 16.5 dpc (n=8).  
 
Tissue collection and leukocyte isolation 
Pregnant mice were euthanized 6 h post-α-GalCer injection or post-DMSO, 
or 4 h post-rosiglitazone treatment (n = 6-8 mice/group). Blood was recovered by 
cardiac puncture, and the myometrial and decidual tissues were collected and 
immediately processed for leukocyte isolation. The spleen and uterine-draining 
lymph nodes (ULNs) were also collected and leukocyte suspensions were 
prepared.  
Leukocyte suspensions from the myometrial and decidual tissues were 
prepared as follows: tissues were cut into small pieces using fine scissors and 
enzymatically digested with StemPro Cell Dissociation Reagent (Accutase; Life 
Technologies, Grand Island, NY, USA) for 35 min at 37°C. Cells from the spleen 
and ULNs were obtained by gentle dissociation using two glass slides. Leukocyte 
suspensions from the myometrium, decidua, spleen, and ULNs were then filtered 
through a 100-µm cell strainer (Fisher Scientific, Hanover Park, IL, USA) and 
washed with FACS buffer [0.1% bovine serum albumin (Sigma-Aldrich), 0.05% 
sodium azide (Fisher Scientific, Fair Lawn, NJ, USA), and 1X PBS (Fisher 
Scientific)].  
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Immunophenotyping  
Aliquots of 100-150 μL of blood were used for immunophenotyping. 
Leukocyte suspensions from the myometrium and decidua were stained with the 
LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Life Technologies) prior to incubation 
with extracellular mAbs. All of the leukocyte suspensions and blood samples were 
centrifuged, and cell pellets were incubated for 10 min with CD16/CD32 mAbs 
(FcγIII/II Receptor, clone 2.4G2; BD Biosciences, San Jose, CA) and subsequently 
incubated with specific fluorochrome-conjugated anti-mouse mAbs: CD1d-tetramer 
loaded with α-GalCer-PE (hereafter referred to as CD1d-tetramer, NIH); 
CD49b/DX5-APC (clone DX5), CD44-APC-Cy7 (clone IM7), CD69-PE-CF594 
(clone H1.2F3), CD3ε-APC Cy7 (clone 145-2C11), CD4-APC (clone RM4-5), 
CD8a-PE-CF594 (clone 53-6.7), CD25-PECy7 (clone PC61), FoxP3-AF488 (clone 
MF23), and IL17A-AF-700 (clone TC11-18H10) (BD Biosciences) for 30 min. 
Leukocyte suspensions were fixed/permeabilized with the Foxp3/Transcription 
Factor Staining Buffer Set (eBioscience, San Diego, CA, USA). At least 50,000 
events for the splenic, decidual, and blood cells or 25,000 events for the ULNs and 
myometrial cells were acquired using the BD LSR Fortessa and FACSDiva 8.0 
software (both from BD Biosciences). Activated CD1d-restricted iNKT cells and T-
cell subsets (cell numbers and mean fluorescence intensity (MFI)) were analyzed 
within the viability gate. Immunophenotyping included identification of  activated 
CD1d-restricted iNKT cells (CD1d-tetramer+DX5+CD69+CD44+ cells), total T cells 
(CD3+ cells), conventional CD4+ and CD8+ T cells (CD3+CD4+ and CD3+CD8+ 
cells), CD4+ regulatory T cells (CD4+ Tregs; CD3+CD4+CD25+Foxp3+ cells), 
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CD8+ regulatory T cells (CD8+ Tregs; CD3+CD8+CD25+Foxp3+ cells), 
CD4+Foxp3- responder T cells (CD3+CD4+CD25+Foxp3- cells), CD8+Foxp3- 
responder T cells (CD3+CD8+CD25+Foxp3- cells), Th17 cells (CD3+CD4+IL17A+ 
cells), and double negative T cells (CD3+CD4-CD8- cells). Data were analyzed 
using the FACSDiva 8.0 software. The total number of T-cell subsets was 
determined using CountBright Absolute Counting Beads (Molecular Probes, Life 
Technologies, Eugene, OR, USA). The figures were created using FlowJo software 
version 10 (TreeStar, Ashland, OR, USA). 
 
Statistical analysis 
Flow cytometry data were analyzed using IBM SPSS Version 19.0 (IBM 
Corporation, Armonk, NY, USA). The statistical significance of group comparisons 
was assessed using the Mann-Whitney U test. A p value of ≤0.05 was considered 
statistically significant. 
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RESULTS 
Administration of α-GalCer induces iNKT-cell activation in the decidua  
First, we confirmed that α-GalCer induced iNKT-cell activation in the decidual 
tissues (19). Activated CD1d-restricted iNKT cells were identified in the decidua by the 
expression of the CD1d-tetramer and DX5 antigen as well as the co-expression of 
CD69 and CD44 antigens (Figure 1A). Administration of α-GalCer induced the 
proliferation of activated CD1d-restricted iNKT cells in the decidua (Figure 1B). 
 
iNKT-cell activation causes a systemic and local reduction of T cells through the 
CD3ε molecule prior to preterm labor/birth 
 We investigated whether iNKT-cell activation via α-GalCer alters systemic and 
local T cells prior to preterm labor/birth. The gating strategy used to determine total T 
cells (CD3+ cells) in the tissues and blood is shown in the decidua and ULNs in 
Supplementary Figure 1. Mice injected with α-GalCer had a reduced number of total T 
cells in the peripheral blood (Figure 2A A), spleen (Figure 2B), ULNs (Figure 2C), and 
myometrium (Figure 2D) compared to the DMSO controls. Although not significant, 
there was a modest reduction in the number of decidual T cells between the mice 
injected with α-GalCer and the DMSO controls (Figure 2E).  
Since we observed a reduction in the total number of T cells, we evaluated the 
mean fluorescence intensity (MFI) of the CD3ε molecule in leukocytes from the 
periphery, lymphatic tissues, and the maternal-fetal interface. Administration of α-
GalCer down-regulated the expression of the CD3ε molecule in the leukocytes from the 
periphery(Figure 3A), spleen (Figure 3B), ULNs (Figure 3C), and decidua (Figure 3E). 
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Administration of α-GalCer did not have any effect on the CD3ε molecule in the 
myometrial leukocytes.  
In order to investigate whether iNKT-cell activation induced cell death in the 
decidua, we evaluated the viability of decidual lymphocytes from mice injected with α-
GalCer or DMSO. There were no differences in the number of viable cells between 
these two groups (Supplementary Figure 2).  
 
iNKT-cell activation causes a systemic and local reduction of  conventional and 
regulatory CD4+ T cells prior to preterm labor/birth 
Conventional and regulatory CD4+ T cells have been implicated in the processes 
of term and preterm labor (19, 31, 33, 34, 36-38, 41). We evaluated whether 
conventional CD4+ T cells would be reduced upon the administration of α-GalCer. The 
gating strat gy used to determine conventional CD4+ T cells in the tissues and blood is 
shown in Figure 4A. Mice injected with α-GalCer had a lower number of conventional 
CD4+ T cells in the peripheral blood (Figure 4B), spleen (Figure 4C), ULNs (Figure 4D), 
and myometrium (Figure 4E) than the DMSO controls. No significant differences were 
observed in the number of conventional CD4+ T cells between the mice injected with α-
GalCer and the DMSO controls in the decidua (Figure 4F).   
Next, we evaluated whether there was a systemic and local reduction of CD4+ 
Tregs prior to iNKT-cell activation-induced preterm labor/birth. The gating strategy used 
to determine CD4+ Tregs in the spleen, ULNs, and decidua is shown in Figure 5A-C. 
Mice injected with α-GalCer had a lower number of CD4+ Tregs in the spleen (Figure 
5D) and ULNs (Figure 5E) than the DMSO controls. The number of decidual CD4+ 
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Tregs also decreased in 62.5% (5/8) of the mice injected with α-GalCer; yet, this 
reduction did not reach statistical significance (Figure 5F). No differences were 
observed in the number of CD4+ Tregs in the peripheral blood and myometrium upon 
administration of α-GalCer (data not shown).  
 
iNKT-cell activation alters the number of Th17 cells in the uterine-draining lymph 
nodes and decidua prior to preterm labor/birth 
An imbalance between the effector Th17 cells and CD4+ Tregs may be 
implicated in the pathogenesis of preterm birth (48). Therefore, we evaluated whether 
there were systemic and local reductions of Th17 cells prior to iNKT-cell activation-
induced preterm labor/birth. The gating strategy used to determine Th17 cells in the 
ULNs, spleen, and decidua is shown in Figure 6A-C. Mice injected with α-GalCer had a 
reduced number of Th17 cells in the ULNs (Figure 6D) and spleen (Figure 6E; not 
significant) compared to the DMSO controls. However, mice injected with α-GalCer had 
a greater number of decidual Th17 cells than the DMSO controls (Figure 6F). No 
differences were observed in the number of Th17 cells in the peripheral blood and 
myometrium upon administration of α-GalCer (data not shown).  
 
iNKT-cell activation causes a systemic and local reduction of CD8+ T cells prior 
to preterm labor/birth 
CD8+ cytotoxic T cells have been implicated in the mechanisms that lead to 
spontaneous preterm labor (40). Next, we evaluated whether CD8+ T cells were 
reduced upon administration of α-GalCer. The gating strategy used to determine CD8+ 
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T cells in the tissues and blood is shown in Figure 7A. Mice injected with α-GalCer had 
a lower number of CD8+ T cells in the peripheral blood (Figure 7B), spleen (Figure 7C), 
ULNs (Figure 7D), myometrium (Figure 7E), and decidua (Figure 7F) than the DMSO 
controls.  
 
iNKT-cell activation causes a reduction of CD8+ regulatory T cells in the spleen 
and uterine-draining lymph nodes prior to preterm labor/birth 
Previous studies have demonstrated that CD8+ Tregs are implicated in the timing 
of term parturition (34) and endotoxin-induced preterm labor/birth (41). Therefore, we 
evaluated whether there was a systemic and local reduction of CD8+ Tregs prior to 
iNKT-cell activation-induced preterm labor/birth. The gating strategy used to determine 
CD8+ Tregs in the spleen and ULNs is shown in Figure 8A and B. Mice injected with α-
GalCer had a lower number of CD8+ Tregs in the spleen (Figure 8C) and ULNs (Figure 
8D) than the DMSO controls. No differences were observed in the number of CD8+ 
Tregs in the peripheral blood, decidua, and myometrium upon administration of α-
GalCer (data not shown).  
 
iNKT-cell activation causes alterations in the number of CD4+ and CD8+ Foxp3- 
responder T cells prior to preterm labor/birth 
 Since we observed a reduction in the number of CD4+ and CD8+ Tregs, we 
evaluated whether iNKT-cell activation via α-GalCer altered the number of CD4+ and 
CD8+ Foxp3- responder T cells. Administration of α-GalCer reduced the number of 
CD4+ and CD8+ Foxp3- responder T cells in the spleen (Figure 9A and D) and ULNs 
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(Figure 9B and E). In the decidua, α-GalCer did not reduce the number of CD4+ Foxp3- 
responder T cells (Figure 9C); however, it partially decreased the number of CD8+ 
Foxp3- responder T cells (Figure 9F).   
 
iNKT-cell activation causes a reduction in the number of double negative T cells 
prior to preterm labor/birth 
Lastly, we evaluated whether there were alterations in the number of double 
negative T cells (CD3+CD4-CD8- cells) prior to iNKT-cell activation-induced preterm 
labor/birth. The gating strategy used to determine double negative T cells in the tissues 
and blood is shown in Supplementary Figure 3A. Mice injected with α-GalCer had a 
reduced number of double negative T cells in the spleen (Supplementary Figure 3C), 
ULNs (Supplementary Figure 3D), myometrium (Supplementary Figure 3E), and 
decidua (Supplementary Figure 3F) compared to the DMSO controls. No significant 
differences were observed in the number of double negative T cells in the peripheral 
blood between the mice injected with α-GalCer and the DMSO controls (Supplementary 
Figure 3B).  
 
Treatment with rosiglitazone partially restores the number of T cells in the spleen 
but not in the decidua 
Previous studies demonstrated that treatment with rosiglitazone prevents 
endotoxin-induced (13) and iNKT-cell activation-induced (19) preterm labor/birth. 
Herein, we investigated whether treatment with rosiglitazone restores the effect of iNKT-
cell activation on systemic and local T cells prior to preterm labor/birth. Treating α-
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GalCer-injected mice with rosiglitazone partially increased the number of total T cells 
(Figure 10A), CD4+ T cells (Figure 10B), and CD8+ T cells (Figure 10C) in the spleen; 
however, such increments did not reach statistical significance. In contrast, treatment 
with rosiglitazone did not restore the T-cell numbers in the decidual tissues (Figure 10D-
F). Further, we investigated whether treatment with rosiglitazone restored the number of 
CD4+ Tregs in the decidua. Treating α-GalCer-injected mice with rosiglitazone did not 
restore the number of CD4+ Tregs in the decidua (Supplementary Figure 4) and spleen 
(data not shown).  
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DISCUSSION 
Principal findings of the study: Administration of α-GalCer induced an expansion of 
CD1d-restricted iNKT cells in the decidua. Prior to iNKT-cell activation-induced preterm 
labor/birth, there was 1) a reduction in the number of total T cells, including CD4+ T 
cells, in the peripheral circulation, spleen, ULNs, and myometrium; 2) a down-regulation 
in the expression of the CD3ε molecule in the circulating, splenic, lymphatic, and 
decidual lymphocytes; 3) a decrease in the number of CD4+ Tregs in the spleen, ULNs, 
and decidua; 4) a reduced number of Th17 cells in the ULNs but an increase in the 
number of such cells in the decidua; 5) a diminished number of CD8+ T cells in the 
peripheral circulation, spleen, ULNs, myometrium, and decidua; 6) a reduction in the 
number of CD8+ Tregs in the spleen and ULNs; and 7) a reduction in the number of 
CD4+ and CD8+ Foxp3- responder T cells in the spleen and ULNs. Treating α-GalCer-
injected mice with rosiglitazone partly restored the number of T cells (CD4+ and CD8+ T 
cells) in the spleen but not in the decidua. Collectively, these data show that iNKT-cell 
activation via α-GalCer induces the down-regulation of the CD3ε molecule, which 
translates to an alteration in the systemic and local T-cell numbers prior to preterm 
labor/birth; yet, treatment with rosiglitazone partially reversed such effects. 
 Recently, we demonstrated that in vivo T-cell activation by administration of a 
monoclonal αCD3ε antibody (clone 145-2C11) induces preterm labor/birth (43). This 
monoclonal αCD3ε antibody activates T cells in the absence of antigens by directly 
recognizing the CD3ε molecule and evading the T-cell receptor (TCR) antigen-specific 
interaction (49, 50). In vitro and in vivo studies have demonstrated that the interaction 
between αCD3ε and the CD3 molecule initiates endocytosis and a temporary loss of the 
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CD3-TCR complex (51-54). Yet, such an interaction simultaneously initiates signaling 
pathways that result in T-cell activation (55-57). Therefore, in vivo and in vitro T-cell 
activation is associated with the temporary loss of the CD3ε molecule (57). In the 
current study, we found that iNKT-cell activation via α-GalCer caused the down-
regulation of the CD3ε molecule, which translated to a reduction in the total number of 
systemic and local T cells.  These findings provide evidence that α-GalCer induces in 
vivo T-cell activation prior to causing preterm labor/birth. In line with this concept, we 
previously demonstrated that prior to iNKT-cell activation-induced preterm labor/birth, 
there is an upregulation of the CD25 and PD1 molecules (activation markers) in the 
myometrial CD4+ T cells (19). In addition, administration of α-GalCer to non-pregnant 
mice induces the upregulation of CD69 (an early activation marker) in splenocytes (58). 
Taken together, these results suggest that α-GalCer causes the systemic and local 
down-regulation of the CD3ε molecule (i.e. T-cell activation) prior to preterm labor/birth. 
In the study herein, we found that lymphatic and decidual CD4+ Tregs were 
reduced prior to iNKT-cell activation-induced preterm labor/birth. CD4+ Tregs are T 
lymphocytes that express the activation marker CD25 and the transcription factor Foxp3 
(59, 60). Their suppressive function is largely due to the expression of Foxp3 (59). 
During pregnancy, there is an expansion of antigen-specific CD4+ Tregs in the spleen 
and at the maternal-fetal interface, which promotes maternal-fetal tolerance and 
pregnancy maintenance (61-64). Indeed, a reduction in the frequency and/or 
suppressive function of circulating CD4+ Tregs is associated with spontaneous preterm 
labor (31, 32, 37, 38, 65, 66). In addition, a decline in the number of CD4+ Tregs at the 
maternal-fetal interface is observed prior to endotoxin-induced preterm labor/birth (41). 
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These data support the hypothesis that a breakdown of maternal-fetal tolerance is a 
mechanism of disease contributing to spontaneous preterm labor (5, 39). Together, 
these findings allow us to hypothesize that iNKT-cell activation via α-GalCer causes a 
breakdown of maternal-fetal tolerance by reducing lymphatic and decidual CD4+ Tregs 
prior to preterm labor/birth. This hypothesis is supported by the fact that activated iNKT 
cells negatively regulate CD4+ Tregs (67).  
Although decidual CD4+Foxp3- responder T cells were not altered prior to iNKT-
cell activation-induced preterm labor/birth, the number of decidual Th17 cells was 
increased. The Th17 cell subset is characterized by the expression of IL17A, IL17F, and 
IL22 (68). The function of these T cells is wide-ranging since these cells can promote or 
regulate tissue inflammation (68, 69). Th17 cells are present in the decidual tissues 
from normal pregnancies (70), and placental hormones (e.g., human chorionic 
gonadotrophin (71)) may be participating in their proliferation/differentiation. Decidual 
Th17 cells are also abundant in the chorionic membranes from women who had 
undergone spontaneous preterm labor with acute histologic chorioamnionitis (72). In 
fact, an imbalance between effector Th17 cells and CD4+ Tregs has been implicated in 
the pathogenesis of preterm birth (48). The data presented herein suggest that iNKT-
cell activation via α-GalCer induces T-cell activation and therefore promotes the 
differentiation of effector Th17 cells at the maternal-fetal interface. This observation is 
concordant with the fact that iNKT-cell activation induces the activation of T cells (19) 
and iNKT null mice (Jα281-/-) have a lower number of Th17 cells (73). Collectively, these 
findings indicate that, prior to iNKT-cell activation-induced preterm labor/birth, there is 
an imbalance between CD4+ Tregs and Th17 cells at the maternal-fetal interface. 
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In addition to altering the number of Th cell subsets, iNKT-cell activation via α-
GalCer reduced the number of lymphatic CD8+ Tregs. Activated CD8+ T cells 
expressing Foxp3 share phenotypic and functional characteristics with classical CD4+ 
Tregs (74). These T cells inhibit T-cell responses (e.g., Th17 cells) in vivo (75). In late 
pregnancy, an expansion of peripheral and decidual CD8+ Tregs was observed when 
IL6 null mice (Il6-/-) received recombinant IL6 in order to restore the timing of parturition 
(34). Altogether, these data suggest that CD8+ Tregs can regulate the timing of 
parturition and that a reduction in the number of these cells may be associated with 
preterm labor/birth. 
Lastly, we showed that treating α-GalCer-injected mice with rosiglitazone, which 
prevents iNKT-cell activation-induced preterm labor/birth (19), partially restores the T-
cell numbers in the spleen. It is well established that PPARγ agonists, such as 
rosiglitazone, inhibit the activation and proliferation of T cells (76, 77). In our model, we 
demonstrated that α-GalCer down-regulated PPARγ gene targets; yet, treatment with 
rosiglitazone restored such effects by activating the PPARγ pathway and preventing 
preterm labor/birth (19). Therefore, restoration of the T-cell numbers in the spleen may 
be explained by the fact that rosiglitazone inhibits iNKT-cell proliferation (19), the initial 
trigger of T-cell activation (i.e., downregulation of the CD3-TCR complex). However, 
treating α-GalCer-injected mice with rosiglitazone did not restore the number of T cells, 
including CD4+ Tregs, at the maternal-fetal interface (i.e., decidua). This finding may 
explain why treatment with rosiglitazone does not prevent preterm birth or improve 
adverse neonatal outcomes entirely. As an alternative, we are currently investigating 
whether treatment with a combination of vaginal progesterone and rosiglitazone can 
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fully prevent iNKT-cell activation-induced preterm labor/birth. Preliminary results show 
that this combination may have protective and synergistic effects (Gomez-Lopez et al.; 
unpublished data). This proposal is based on the finding that treating endotoxin-injected 
mice with vaginal progesterone increases the frequency of CD4+ Tregs in the decidua 
and prevents preterm labor/birth (78).  
In summary, the study herein showed that iNKT-cell activation via α-GalCer 
induced T-cell activation (i.e. down-regulation of the CD3ε molecule), which translated 
to a systemic and local alteration in T-cell subsets prior to preterm labor/birth; yet, 
treatment with rosiglitazone partially restored such effects (Figure 11). Previously, we 
demonstrated that in vivo iNKT-cell activation induces the activation of the innate 
immune system (macrophages, dendritic cells and neutrophils) and decidual cells 
(maternal-fetal interface) prior to preterm labor and birth, which is also attenuated upon 
treatment with rosiglitazone (19) (Figure 11). Together, these findings provide evidence 
that both innate and adaptive immune cells are implicated in the pathogenesis of 
preterm labor and that PPARγ activation can represent a new streategy for the 
prevention of this syndrome (Figure 11). Yet, a combination of several therapeutic 
approaches may be required in order to prevent preterm labor/birth entirely and improve 
adverse neonatal outcomes.   
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
22 
 
ACKNOWLEDGEMENTS  
This research was fully supported by the Wayne State University Perinatal Initiative in 
Maternal, Perinatal and Child Health. RR is supported by the Perinatology Research 
Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of 
Child Health and Human Development, National Institutes of Health, U. S. Department 
of Health and Human Services (NICHD/NIH/DHHS). We gratefully acknowledge 
Maureen McGerty, M.A., (Wayne State University) for her critical readings of the 
manuscript.  
 
DECLARATION OF CONFLICTING INTERESTS 
The authors declared no potential conflicts of interest. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
23 
 
REFERENCES 
1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. 
National, regional, and worldwide estimates of preterm birth rates in the year 2010 with 
time trends since 1990 for selected countries: a systematic analysis and implications. 
Lancet. 2012;379(9832):2162-72. 
2. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and 
national causes of child mortality in 2000-13, with projections to inform post-2015 
priorities: an updated systematic analysis. Lancet. 2015;385(9966):430-40. 
3. Romero R, Mazor M, Munoz H, Gomez R, Galasso M, Sherer DM. The preterm 
labor syndrome. Ann N Y Acad Sci. 1994;734:414-29. 
4. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of 
preterm birth. Lancet. 2008;371(9606):75-84. 
5. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. 
Science. 2014;345(6198):760-5. 
6. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role 
of inflammation and infection in preterm birth. Semin Reprod Med. 2007;25(1):21-39. 
7. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, et al. The 
preterm parturition syndrome. BJOG. 2006;113 Suppl 3:17-42. 
8. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel LA, Nien JK. 
Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med. 
2006;11(5):317-26. 
9. Kim YM, Romero R, Chaiworapongsa T, Kim GJ, Kim MR, Kuivaniemi H, et al. 
Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
24 
 
term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet 
Gynecol. 2004;191(4):1346-55. 
10. Cardenas I, Means RE, Aldo P, Koga K, Lang SM, Booth CJ, et al. Viral infection 
of the placenta leads to fetal inflammation and sensitization to bacterial products 
predisposing to preterm labor. J Immunol. 2010;185(2):1248-57. 
11. Vaisbuch E, Romero R, Erez O, Mazaki-Tovi S, Kusanovic JP, Soto E, et al. 
Activation of the alternative pathway of complement is a feature of pre-term parturition 
but not of spontaneous labor at term. Am J Reprod Immunol. 2010;63(4):318-30. 
12. Romero R, Chaiworapongsa T, Alpay Savasan Z, Xu Y, Hussein Y, Dong Z, et 
al. Damage-associated molecular patterns (DAMPs) in preterm labor with intact 
membranes and preterm PROM: a study of the alarmin HMGB1. J Matern Fetal 
Neonatal Med. 2011;24(12):1444-55. 
13. Xu Y, Romero R, Miller D, Kadam L, Mial TN, Plazyo O, et al. An M1-like 
Macrophage Polarization in Decidual Tissue during Spontaneous Preterm Labor That Is 
Attenuated by Rosiglitazone Treatment. J Immunol. 2016;196(6):2476-91. 
14. Gomez-Lopez N, Romero R, Plazyo O, Panaitescu B, Furcron AE, Miller D, et al. 
Intra-Amniotic Administration of HMGB1 Induces Spontaneous Preterm Labor and Birth. 
Am J Reprod Immunol. 2016;75(1):3-7. 
15. Gomez-Lopez N, Romero R, Xu Y, Miller D, Unkel R, Shaman M, et al. 
Neutrophil Extracellular Traps in the Amniotic Cavity of Women with Intra-Amniotic 
Infection: A New Mechanism of Host Defense. Reprod Sci. 2016. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
25 
 
16. Gomez-Lopez N, Romero R, Xu Y, Plazyo O, Unkel R, Leng Y, et al. A Role for 
the Inflammasome in Spontaneous Preterm Labor With Acute Histologic 
Chorioamnionitis. Reprod Sci. 2017:1933719116687656. 
17. Li LP, Fang YC, Dong GF, Lin Y, Saito S. Depletion of invariant NKT cells 
reduces inflammation-induced preterm delivery in mice. J Immunol. 2012;188(9):4681-
9. 
18. Li L, Yang J, Jiang Y, Tu J, Schust DJ. Activation of decidual invariant natural 
killer T cells promotes lipopolysaccharide-induced preterm birth. Mol Hum Reprod. 
2015;21(4):369-81. 
19. St Louis D, Romero R, Plazyo O, Arenas-Hernandez M, Panaitescu B, Xu Y, et 
al. Invariant NKT Cell Activation Induces Late Preterm Birth That Is Attenuated by 
Rosiglitazone. J Immunol. 2016;196(3):1044-59. 
20. Kos ki H, Imai K, Nakayama F, Sado T, Moriwaki K, Taniguchi M. Homogenous 
junctional sequence of the V14+ T-cell antigen receptor alpha chain expanded in 
unprimed mice. Proc Natl Acad Sci U S A. 1990;87(14):5248-52. 
21. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An 
invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals 
by clonally expanded CD4-8- T cells. J Exp Med. 1994;180(3):1171-6. 
22. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 
2007;25:297-336. 
23. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-
producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat 
Immunol. 2002;3(9):867-74. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
26 
 
24. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular 
mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J 
Clin Invest. 2004;113(11):1631-40. 
25. Sag D, Krause P, Hedrick CC, Kronenberg M, Wingender G. IL-10-producing 
NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Invest. 
2014;124(9):3725-40. 
26. Wang J, Cao X, Zhao J, Zhao H, Wei J, Li Q, et al. Critical roles of conventional 
dendritic cells in promoting T cell-dependent hepatitis through regulating natural killer T 
cells. Clin Exp Immunol. 2016. 
27. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted 
and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 
1997;278(5343):1626-9. 
28. Chen Q, Ross AC. alpha-Galactosylceramide stimulates splenic lymphocyte 
proliferation in vitro and increases antibody production in vivo in late neonatal-age mice. 
Clin Exp Immunol. 2015;179(2):188-96. 
29. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells: bridging innate and 
adaptive immunity. Cell Tissue Res. 2011;343(1):43-55. 
30. Gomez-Lopez N, Vadillo-Perez L, Hernandez-Carbajal A, Godines-Enriquez M, 
Olson DM, Vadillo-Ortega F. Specific inflammatory microenvironments in the zones of 
the fetal membranes at term delivery. Am J Obstet Gynecol. 2011;205(3):235 e15-24. 
31. Schober L, Radnai D, Schmitt E, Mahnke K, Sohn C, Steinborn A. Term and 
preterm labor: decreased suppressive activity and changes in composition of the 
regulatory T-cell pool. Immunol Cell Biol. 2012;90(10):935-44. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
27 
 
32. Gomez-Lopez N, Laresgoiti-Servitje E. T regulatory cells: regulating both term 
and preterm labor? Immunol Cell Biol. 2012;90(10):919-20. 
33. Gomez-Lopez N, Vega-Sanchez R, Castillo-Castrejon M, Romero R, Cubeiro-
Arreola K, Vadillo-Ortega F. Evidence for a role for the adaptive immune response in 
human term parturition. Am J Reprod Immunol. 2013;69(3):212-30. 
34. Gomez-Lopez N, Olson DM, Robertson SA. Interleukin-6 controls uterine Th9 
cells and CD8(+) T regulatory cells to accelerate parturition in mice. Immunol Cell Biol. 
2016;94(1):79-89. 
35. Steinborn A, Schmitt E, Stein Y, Klee A, Gonser M, Seifried E, et al. Prolonged 
preterm rupture of fetal membranes, a consequence of an increased maternal anti-fetal 
T cell responsiveness. Pediatr Res. 2005;58(4):648-53. 
36. Bizargity P, Del Rio R, Phillippe M, Teuscher C, Bonney EA. Resistance to 
lipopolysaccharide-induced preterm delivery mediated by regulatory T cell function in 
mice. Biol Reprod. 2009;80(5):874-81. 
37. Kisielewicz A, Schaier M, Schmitt E, Hug F, Haensch GM, Meuer S, et al. A 
distinct subset of HLA-DR+-regulatory T cells is involved in the induction of preterm 
labor during pregnancy and in the induction of organ rejection after transplantation. Clin 
Immunol. 2010;137(2):209-20. 
38. Steinborn A, Schmitt E, Kisielewicz A, Rechenberg S, Seissler N, Mahnke K, et 
al. Pregnancy-associated diseases are characterized by the composition of the 
systemic regulatory T cell (Treg) pool with distinct subsets of Tregs. Clin Exp Immunol. 
2012;167(1):84-98. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
28 
 
39. Gomez-Lopez N, StLouis D, Lehr MA, Sanchez-Rodriguez EN, Arenas-
Hernandez M. Immune cells in term and preterm labor. Cell Mol Immunol. 
2014;11(6):571-81. 
40. Kim CJ, Romero R, Chaemsaithong P, Kim JS. Chronic inflammation of the 
placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet 
Gynecol. 2015;213(4 Suppl):S53-69. 
41. Arenas-Hernandez M, Romero R, St Louis D, Hassan SS, Kaye EB, Gomez-
Lopez N. An imbalance between innate and adaptive immune cells at the maternal-fetal 
interface occurs prior to endotoxin-induced preterm birth. Cell Mol Immunol. 2015. 
42. Bonney EA. Immune Regulation in Pregnancy: A Matter of Perspective? Obstet 
Gynecol Clin North Am. 2016;43(4):679-98. 
43. Gomez-Lopez N, Romero R, Arenas-Hernandez M, Ahn HJ, Panaitescu B, 
Vadillo-Ort ga F, et al. In vivo T-cell activation by a monoclonal αCD3ε antibody 
induces preterm labor and birth. Am J Reprod Immunol. 2016:In press. 
44. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-
activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270(22):12953-6. 
45. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-
activated receptor-gamma is a negative regulator of macrophage activation. Nature. 
1998;391(6662):79-82. 
46. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation 
of proliferator-activated receptors alpha and gamma induces apoptosis of human 
monocyte-derived macrophages. J Biol Chem. 1998;273(40):25573-80. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
29 
 
47. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. 
Peroxisome proliferator-activated receptor activators inhibit thrombin-induced 
endothelin-1 production in human vascular endothelial cells by inhibiting the activator 
protein-1 signaling pathway. Circ Res. 1999;85(5):394-402. 
48. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell 
paradigm in pregnancy. Am J Reprod Immunol. 2010;63(6):601-10. 
49. Meuer SC, Hodgdon JC, Hussey RE, Protentis JP, Schlossman SF, Reinherz 
EL. Antigen-like effects of monoclonal antibodies directed at receptors on human T cell 
clones. J Exp Med. 1983;158(3):988-93. 
50. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a 
monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A. 
1987;84(5):1374-8. 
51. Reinherz EL, Meuer S, Fitzgerald KA, Hussey RE, Levine H, Schlossman SF. 
Antigen recognition by human T lymphocytes is linked to surface expression of the T3 
molecular complex. Cell. 1982;30(3):735-43. 
52. Krangel MS. Endocytosis and recycling of the T3-T cell receptor complex. The 
role of T3 phosphorylation. J Exp Med. 1987;165(4):1141-59. 
53. Minami Y, Samelson LE, Klausner RD. Internalization and cycling of the T cell 
antigen receptor. Role of protein kinase C. J Biol Chem. 1987;262(27):13342-7. 
54. von Essen M, Bonefeld CM, Siersma V, Rasmussen AB, Lauritsen JP, Nielsen 
BL, et al. Constitutive and ligand-induced TCR degradation. J Immunol. 
2004;173(1):384-93. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
30 
 
55. Ellenhorn JD, Schreiber H, Bluestone JA. Mechanism of tumor rejection in anti-
CD3 monoclonal antibody-treated mice. J Immunol. 1990;144(7):2840-6. 
56. Schneider E, Salaun V, Ben Amor A, Dy M. Hematopoietic changes induced by a 
single injection of anti-CD3 monoclonal antibody into normal mice. Stem Cells. 
1997;15(2):154-60. 
57. Lal G, Shaila MS, Nayak R. Activated mouse T cells downregulate, process and 
present their surface TCR to cognate anti-idiotypic CD4+ T cells. Immunol Cell Biol. 
2006;84(2):145-53. 
58. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting 
edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate 
NK cells. J Immunol. 1999;163(9):4647-50. 
59. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the 
transcription factor Foxp3. Science. 2003;299(5609):1057-61. 
60. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330-6. 
61. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal 
tolerance to the fetus. Nat Immunol. 2004;5(3):266-71. 
62. Kahn DA, Baltimore D. Pregnancy induces a fetal antigen-specific maternal T 
regulatory cell response that contributes to tolerance. Proc Natl Acad Sci U S A. 
2010;107(20):9299-304. 
63. Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory memory that 
sustains anergy to fetal antigen. Nature. 2012;490(7418):102-6. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
31 
 
64. Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. Extrathymic 
generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. 
Cell. 2012;150(1):29-38. 
65. Xiong H, Zhou C, Qi G. Proportional changes of CD4+CD25+Foxp3+ regulatory 
T cells in maternal peripheral blood during pregnancy and labor at term and preterm. 
Clin Invest Med. 2010;33(6):E422. 
66. Kalble F, Mai C, Wagner M, Schober L, Schaier M, Zeier M, et al. Aberrant 
ICOS+ -T cell differentiation in women with spontaneous preterm labor. Am J Reprod 
Immunol. 2016;76(5):415-25. 
67. Hong H, Gu Y, Zhang H, Simon AK, Chen X, Wu C, et al. Depletion of 
CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour 
immunity in a murine mammary breast cancer model. Clin Exp Immunol. 
2010;159(1):93-9. 
68. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage 
of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 
2005;6(11):1133-41. 
69. Bellemore SM, Nikoopour E, Krougly O, Lee-Chan E, Fouser LA, Singh B. 
Pathogenic T helper type 17 cells contribute to type 1 diabetes independently of 
interleukin-22. Clin Exp Immunol. 2016;183(3):380-8. 
70. Nakashima A, Ito M, Yoneda S, Shiozaki A, Hidaka T, Saito S. Circulating and 
decidual Th17 cell levels in healthy pregnancy. Am J Reprod Immunol. 2010;63(2):104-
9. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
32 
 
71. Furcron AE, Romero R, Mial TN, Balancio A, Panaitescu B, Hassan SS, et al. 
Human Chorionic Gonadotropin Has Anti-Inflammatory Effects at the Maternal-Fetal 
Interface and Prevents Endotoxin-Induced Preterm Birth, but Causes Dystocia and 
Fetal Compromise in Mice. Biol Reprod. 2016;94(6):136. 
72. Ito M, Nakashima A, Hidaka T, Okabe M, Bac ND, Ina S, et al. A role for IL-17 in 
induction of an inflammation at the fetomaternal interface in preterm labour. J Reprod 
Immunol. 2010;84(1):75-85. 
73. Yoshiga Y, Goto D, Segawa S, Ohnishi Y, Matsumoto I, Ito S, et al. Invariant 
NKT cells produce IL-17 through IL-23-dependent and -independent pathways with 
potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med. 
2008;22(3):369-74. 
74. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, et al. Human 
CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ 
regulatory thymocytes. Blood. 2003;102(12):4107-14. 
75. Nakagawa T, Tsuruoka M, Ogura H, Okuyama Y, Arima Y, Hirano T, et al. IL-6 
positively regulates Foxp3+CD8+ T cells in vivo. Int Immunol. 2010;22(2):129-39. 
76. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of 
human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma 
(PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J 
Biol Chem. 2000;275(7):4541-4. 
77. Choi JM, Bothwell AL. The nuclear receptor PPARs as important regulators of T-
cell functions and autoimmune diseases. Mol Cells. 2012;33(3):217-22. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
33 
 
78. Furcron AE, Romero R, Plazyo O, Unkel R, Xu Y, Hassan SS, et al. Vaginal 
progesterone, but not 17alpha-hydroxyprogesterone caproate, has antiinflammatory 
effects at the murine maternal-fetal interface. Am J Obstet Gynecol. 2015;213(6):846 
e1- e19. 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
34 
 
FIGURE LEGENDS 
Figure 1. Administration of α-GalCer induces an expansion of activated CD1d-
restricted iNKT cells in decidual tissues. (A) Gating strategy used to identify activated 
CD1d-restricted iNKT cells (CD1d tetramer+DX5+CD69+CD44+ cells) in decidual 
tissues. (B) Number of CD1d-restricted iNKT cells in decidual tissues from mice injected 
with DMSO or α-GalCer (N=6-8 each).  
Figure 2. iNKT-cell activation via α-GalCer causes a systemic and local 
reduction of T cells. The number of T cells in the peripheral blood (A), spleen (B), 
uterine-draining lymph nodes (ULNs; C), myometrium (D), and decidua (E) from mice 
injected with DMSO or α-GalCer (N=6-8 each). T cells were gated within the viability 
gate. 
Figure 3. iNKT-cell activation via α-GalCer down-regulates the CD3ε molecule 
locally and systemically. Mean fluorescence intensity of the CD3ε molecule in 
leukocytes from the periphery (A), spleen (B), uterine-draining lymph nodes (ULNs; C), 
myometrium (D), and decidua (E) from mice injected with DMSO or α-GalCer (N=6-8 
each).  
Figure 4. iNKT-cell activation via α-GalCer causes a systemic and local 
reduction of CD4+ T cells. The gating strategy used to determine CD4+ T cells 
(CD3+CD4+CD8- cells) in the peripheral blood and in the lymphatic, myometrial, and 
decidual tissues (A). CD4+ T cells were gated within the CD3+ and viability gates. The 
number of CD4+ T cells in the peripheral blood (B), spleen (C), uterine-draining lymph 
nodes (ULNs; D), myometrium (E), and decidua (F) from mice injected with DMSO or α-
GalCer (N=6-8 each). 
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Figure 5. iNKT-cell activation via α-GalCer causes a systemic and local 
reduction of CD4+ Tregs. The gating strategy used to determine CD4+ Tregs 
(CD3+CD4+CD25+Foxp3+ cells) in the spleen (A), uterine-draining lymph nodes 
(ULNs; B), and decidua (C). CD4+ Tregs were gated within the CD3+CD4+ and viability 
gates. The number of CD4+ Tregs in the spleen (D), ULNs (E), and decidua (F) from 
mice injected with DMSO or α-GalCer (N=6-8 each). 
Figure 6. iNKT-cell activation via α-GalCer alters the number of Th17 cells in the 
uterine-draining lymph nodes and decidua. The gating strategy used to determine Th17 
cells (CD3+CD4+IL17A+ cells) in the uterine-draining lymph nodes (ULNs; A), spleen 
(B), and decidua (C). Th17 cells are defined as CD4+ T cells expression IL17A (right top 
quadrant). Th17 cells were gated within the CD3+ and viability gates. The number of 
Th17 cells in the ULNs (D), spleen (E), and decidua (F) from mice injected with DMSO 
or α-GalCer (N=6-8 each). 
Figure 7. iNKT-cell activation via α-GalCer causes the systemic and local 
reduction of CD8+ T cells. The gating strategy used to determine CD8+ T cells 
(CD3+CD8+CD4- cells) in the peripheral blood and in the lymphatic, myometrial, and 
decidual tissues (A). CD8+ T cells were gated within the CD3+ gate. The number of 
CD8+ T cells in the peripheral blood (B), spleen (C), uterine-draining lymph nodes 
(ULNs; D), myometrium (E), and decidua (F) from mice injected with DMSO or α-GalCer 
(N=6-8 each). 
Figure 8. iNKT-cell activation via α-GalCer causes a reduction of lymphatic 
CD8+ Tregs. The gating strategy used to determine CD8+ Tregs 
(CD3+CD8+CD25+Foxp3+ cells) in the spleen (A) and uterine-draining lymph nodes 
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(ULNs; B). CD8+ Tregs were gated within the CD3+CD8+ gate. The number of CD8+ 
Tregs in the spleen (C) and ULNs (D) from mice injected with DMSO or α-GalCer (N=6-
8 each). 
Figure 9. iNKT-cell activation via α-GalCer causes a reduction of CD4+ and 
CD8+ Foxp3- responder T cells in the spleen and uterine-draining lymph nodes. 
Number of CD4+Foxp3- responder T cells (CD3+CD4+CD25+Foxp3- cells) in the 
spleen (A), uterine-draining lymph nodes (ULNs; B), and decidua (C) from mice injected 
with DMSO or α-GalCer (N=6-8 each). Number of CD8+Foxp3- responder T cells 
(CD3+CD8+CD25+Foxp3- cells) in the spleen (D), uterine-draining lymph nodes (ULNs; 
E), and decidua (F) from mice injected with DMSO or α-GalCer (N=6-8 each). 
Figure 10. Treating α-GalCer-injected mice with rosiglitazone partially restored 
the T-cell numbers in the spleen but not in the decidua. Number of T cells (A and D), 
CD4+ T cells (B and E), and CD8+ T cells (C and F) in the spleen and decidua from 
mice injected with α-GalCer, rosiglitazone (Rosi), or α-GalCer plus rosiglitazone (N=6-8 
each). 
Figure 11. In vivo iNKT-cell activation induces preterm labor/birth by initiating adaptive 
and innate immune responses. In vivo iNKT-cell activation via α-GalCer induces T-cell activation 
(down-regulation of the CD3ε molecule), which translates into alterations in T-cell subsets at the 
maternal-fetal interface prior to preterm labor and birth. In addition, in vivo iNKT-cell activation 
induces the activation of the innate immune system and decidual cells (maternal-fetal interface) 
prior to preterm labor and birth (19). PPARγ activation via treatment with rosiglitazone could 
partially restore such effects and prevent preterm labor and birth.  
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